Objectives. RA associates with increased cardiovascular disease (CVD) morbidity and mortality due to accelerated atherosclerosis, attributed to both classical risk factors and chronic inflammation. The aim of this study was to test the hypothesis that effective disease control over 3 years modifies acceleration of atherosclerosis in RA.
Introduction
It is well accepted that RA associates with increased morbidity and mortality due to accelerated cardiovascular disease (CVD) and formation of atherosclerotic lesions that might be more prone to rupture [13] . RA is characterized by increased prevalence of classical CVD risk factors such as arterial hypertension, hyperlipidaemia and insulin resistance compared with the general population [46] . However, even in the absence of such factors, RA patients present with accelerated atherosclerosis [2, 7] . This could be due to chronic systemic inflammation, which may promote atherosclerosis not only by modulating classical CVD risk factors [8] , but also via overexpression of proinflammatory cytokines such as TNF and IL-6, which directly affect the vasculature [2] . Given that TNF and IL-6, among other mediators of inflammation, have been directly implicated in atherosclerosis, biologic drugs that block these cytokines could have beneficial effects on cardiovascular risk beyond those deriving from controlling inflammation [2, 9, 10] . While the close relationship between RA and CVD is now accepted, studies on the progression of atherosclerosis in patients with low disease activity and on possible drug-specific effects are lacking [2, 11] .
The aims of the present longitudinal study were to test the hypotheses (i) that the rate of progression of carotid and femoral/arterial atherosclerosis over 3 years is not increased in RA patients who are in remission or have low disease activity compared with non-RA controls with comparable burden of traditional CVD risk factors; (ii) that in well-controlled patients, progression of subclinical atherosclerosis does not differ between those receiving biologic and those receiving synthetic DMARDs.
Methods

Patients and controls
Consecutive, non-diabetic RA patients, who met the 1987 ACR criteria and had been previously examined by ultrasonography for atherosclerosis in our centre, were reevaluated after 3.2 (0.2) years. At baseline, none had known CVD, malignancy, chronic renal failure or other chronic or acute inflammatory disease. In addition to their consent, the only two inclusion criteria in the longitudinal study were regular follow-up, that is, at least every 4 months during the whole follow-up period; and effective disease control, determined arbitrarily as the presence of remission or of low disease activity (DAS28 <3.2) for at least 75% of the follow-up period.
RA patients were matched for age and gender with nondiabetic, non-RA control individuals who were studied in parallel [mean follow-up of 3.1 (0.2) years] and were free of CVD at baseline, as well as malignancy, chronic renal failure or any chronic or acute inflammatory disease at both baseline and follow-up end. Our control group consisted of volunteering employees at Laikon Hospital, as well as of individuals referred to our laboratory for suspected arterial hypertension and/or for cardiovascular examination. In order to test whether progression of subclinical atherosclerosis in our patients does not differ between those receiving biologic and those receiving synthetic DMARDs, we also performed a subgroup analysis by matching all biologic-treated patients (n = 56) for age and gender with 56 of the remaining 83 patients. Of DMARDtreated patients, 29 were receiving methotrexate (weekly doses ranging from 7.5 to 17.5 mg). This study was approved by the Laikon General Hospital Institunional Review Board and all subjects provided informed consent according to the Declaration of Helsinki.
Evaluation of vascular indices
All patients and controls were comprehensively studied by US [12] at baseline and follow-up end for the following: arterial stiffness by pulse wave velocity (PWV); arterial hypertrophy assessed by intimamedia thickness (IMT) of the left common carotid artery measured at different sites from plaques (average of two measurements); and atheromatosis extent, by the possible presence of carotid artery and/or femoral artery plaques at eight arterial sites (left and right common and internal carotid arteries and carotid bulb and both common femoral arteries). Plaques were defined as local increase of the IMT of >50% compared with the surrounding vessel wall, an IMT >1.5 mm, or local thickening >0.5 mm [12] . All measurements were performed manually by the same technician using highresolution B-mode ultrasound (Vivid 7 Pro, GE Healthcare, Milwaukee, USA) with a 14-MHz multi-frequency linear transducer and pulse wave analysis methodology (Sphygmocor, AtCor, Sydney, Australia) as described [12] .
Statistical analysis
Normality of sample distribution was examined by the KolmogorovSmirnov test. Continuous variables are presented as mean (S.D.) when sample had a normal distribution, or median and 25th and 75th percentile values [interquartile range (IQR)] for non-normally distributed samples. Categorical variables are presented as percentiles. For comparison of continuous or categorical variables we used Student's paired t-test or the chi-square test, respectively. We used multivariate logistic regression models, before and after correcting for the presence of intermediates/confounders, to compare the probability for the formation of new atheromatic plaques or the yearly progression rate of IMT between the two groups. The selection of CVD risk factors as potential intermediates/confounders was based on their clinical use as suggested by worldwide recommendations for screening for total CVD risk [12] . Moreover, RA disease duration, family history of CVD, difference in BMI, anti-hypertensive and lipid-lowering drugs, and baseline vascular status were further included in the analysis. Stata version 12 (StataCorp, College Station, TX, USA) was used for all analyses and P < 0.05 was considered as the level of statistical significance in all cases.
Results
Characteristics of patients and controls
A total of 139 RA patients, aged 56.7 (11.7) years, 16% men, with median disease duration of 7 years at baseline (IQR: 213 years) were re-evaluated by ultrasound after 3.2 (0.2) years (Table 1) . During the follow-up period disease remission or low activity had been achieved with the target to treat approach; at follow-up end 56 patients were receiving biologic therapy, combined with MTX (n = 23), www.rheumatology.oxfordjournals.org other synthetic DMARDs (n = 6), or given as monotherapy (n = 27). Of the remaining patients, 49 were receiving MTX (8 of whom combined with HCQ), 14 LEF (3 of whom combined with HCQ), 6 HCQ and 14 low dose prednisolone only. Prednisolone, always at doses lower than 7.5 mg, had been used at follow-up end by 58% of patients and none of the controls.
The burden of classical CVD risk factors, such as family history of CVD, smoking, arterial hypertension and hyperlipidaemia, was comparable between RA patients and non-RA controls, both at baseline and follow-up end (Table 1) . Moreover, numbers of subjects under antihypertensive or lipid-lowering treatment were comparable between groups; a marginal difference was only noted regarding the number of subjects in whom anti-hypertensive was added during follow-up, which was higher among controls (Table 1) . BMI was similar between RA patients and controls (Table 1) .
Atherosclerosis indices and their changes in patients and controls
Vascular indices under study at baseline and at follow-up end in RA patients and their matched non-RA controls are shown in Table 1 . The median yearly PWV change was 0.07 m/s (IQR: À0.15, 0.27) for RA patients vs À0.06 m/s (IQR: À0.26, 0.13) in controls. Carotid intimamedia thickness in the left common carotid artery increased per year by 0.009 mm (IQR: 0.0010.023) in RA patients vs 0.011 mm (IQR: 00.022) in controls. New atheromatic plaques in carotid and/or femoral arterial beds were seen in 22% of RA patients vs 25% of controls. By multivariate analysis models, no statistically significant differences for any of the evaluated markers of subclinical CVD were found between RA patients and controls (Table 1) . Two patients vs one control developed clinical CVD during follow-up.
Progression of atherosclerosis indices in patients treated with biologic vs synthetic DMARDs
The two RA subgroups did not differ in terms of traditional CVD risk factors (Table 2) ; proportions of RF and CCP positivity were lower in the DMARD-treated than the biologic-treated group, albeit not significantly. After correction for possible confounders, no difference was evident in any of the vascular indices examined between the two subgroups. Multivariate analysis did not reveal any significant effect of disease duration, low dose prednisolone or MTX treatment, any modification of anti-hypertensive or lipid-lowering therapies, or of RF or anti-CCP status on any of the evaluated vascular indices (data not shown).
Discussion
This is the first study to show that sufficient control of inflammation in patients with RA associates with rates of atherosclerosis progression seen in people without RA and otherwise similar CVD risk factor burden. Moreover, to the best of our knowledge, this is the first longitudinal study in RA evaluating the progression rate of three different parameters of subclinical atherosclerosis, that is, arterial stiffness, common carotid artery hypertrophy and carotid and femoral atheromatic plaques, the combination of which may predict CVD event in these patients [13, 14] . Although the rate of IMT progression in our study is lower when compared with rates reported elsewhere, it should be noted that patients and controls studied herein were regularly followed up, and therefore, classical CVD risk factors were under strict control. In any case, distribution of IMT values is too heterogeneous between studies so that reference values cannot be defined [15] .
Indeed, observational studies suggest that the higher the inflammatory load, the more accelerated the processes of atherosclerosis become [16] . Other studies have shown that mediators participating in inflammatory pathways, such as TNF and IL-6, are associated with acceleration of atherosclerosis and could be markers of arterial disease, even implying a common aetiological pathway between RA and CVD [17, 18] . This may well be true for active RA [16] . The results of the present prospective study demonstrate that in the presence of low disease activity and/or remission, the development of atherosclerosis is not accelerated, suggesting that any further development may be largely due to classical risk factors. Our recent study in patients with AS, albeit cross sectional, as well as a relevant meta-analysis, also concluded that control of inflammation associates with atherosclerosis progression rates seen in people without AS [19] .
The use of biologic DMARDs has been associated with improved arterial morphology and function [9] and better CVD outcomes [20] in patients with RA. It remains unclear whether this is indirectly attributed to effective control of inflammation or to neutralization of specific cytokine effects implicated in atherogenesis, such as TNF and IL-6, the levels of which are known to predict cardiovascular mortality, independently of cardiovascular risk factors [2, 3] . Interestingly, in our study differences in all examined vascular indices were similar between RA patients receiving biologic therapy and those under conventional DMARDs, suggesting that acceleration of atherosclerosis is abrogated regardless of treatment modalities used to suppress inflammation.
Based on the current treat-to-target approach for RA, early disease diagnosis and optimized treatment are essential for achieving long-term health-related quality of life, not only regarding directly related disease symptoms, but also induced comorbidities. In this notion, early control of RA disease activity, as well as classical cardiovascular risk factors, could minimize risk for developing CVD. In our cohort of RA patients in remission or with low disease activity, we did not note an acceleration of subclinical CVD, ensuring minimum impact of RA disease.
Regarding our study limitations, it should be noted that some control subjects had been referred to us for suspected arterial hypertension, while patients had been already followed up in our centre, thus having probably more effective control of traditional CVD risk factors. Thus, a larger proportion of control subjects than patients www.rheumatology.oxfordjournals.org either initiated or changed their anti-hypertensive or lipidlowering therapy after the baseline evaluation (Table 1) . This could explain differences between the two groups, especially regarding PWV, which is predominantly affected by arterial pressure.
To conclude, effective inflammation control, which may not be drug-specific, seems to de-accelerate the progression of atherosclerosis in RA to the rate observed in non-RA controls. Whether early and sustained disease control also translates to the rates expected for the general population of cardiovascular morbidity and mortality in RA patients remains to be proven in large prospective cohort studies. Nevertheless, the current therapeutic strategy, based on the treat-to-target approach, should include prompt control of joint disease, as well as of cardiovascular risk factors. 
